Department of Neurosurgery, Allen Memorial Hospital, UnityPoint Clinic, 146 W Dale Street Suite 201, Waterloo, IA 50703, USA.
Neurosurg Clin N Am. 2021 Jul;32(3):389-395. doi: 10.1016/j.nec.2021.03.010. Epub 2021 May 7.
This article provides a review of current pharmacologic and cell-based modalities used for the management of acute spinal cord injury (SCI). The literature search was focused on clinical trials performed in the United States and Canada. Despite the significant advance in research, there is no definitive treatment option for SCI. Instead, existing pharmacologic and cell-based modalities provide only minimal neurologic recovery benefits. This can be attributed to the complex pathophysiology of SCI and spinal cord regeneration. Further research is imperative to better understand these mechanisms and discover definitive treatment modalities.
这篇文章回顾了目前用于治疗急性脊髓损伤 (SCI) 的药物和基于细胞的治疗方法。文献检索主要集中在美国和加拿大进行的临床试验。尽管研究取得了重大进展,但 SCI 仍然没有明确的治疗选择。相反,现有的药物和基于细胞的治疗方法只能提供有限的神经恢复益处。这可以归因于 SCI 和脊髓再生的复杂病理生理学。进一步的研究对于更好地了解这些机制和发现明确的治疗方法至关重要。